|
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) |
|
Hepion Pharmaceuticals Inc
HEPA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Hepion Pharmaceuticals Inc 's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Hepion Pharmaceuticals Inc net loss decreased from $-11 millions, to $-5 millions in III. Quarter 2024,
• More on HEPA's Growth
|
|
Hepion Pharmaceuticals Inc realized a net loss in trailing twelve months.
Hepion Pharmaceuticals Inc realized cash reduction of $ -2.65 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
• More on HEPA's Valuation
|
|
|
|
|
Hepion Pharmaceuticals Inc realized net loss in trailing twelve months.
Hepion Pharmaceuticals Inc realized cash outflow of $ -2.65per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
• More on HEPA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com